Research Activity – Page 24

Merck’s Keytruda Achieves Industry-First Success in Preventing Head and Neck Cancer Recurrence: AACR 2025 Highlights

6 months ago talkbio0Tagged AACR, Cancer of Neck, Clinical Trials, Event-Free Survival, Head, KEYNOTE-689 trial, Keytruda, locally advanced head, Merck, pembrolizumab, perioperative, recurrence prevention, Squamous cell carcinoma, United States Food and Drug Administration

Keytruda; Merck; AACR 2025; head and neck cancer; resectable locally advanced head and neck squamous cell carcinoma; event-free survival; KEYNOTE-689 trial; perioperative pembrolizumab; recurrence prevention; clinical trial; FDA

GSK and iTeos End Belrestotug TIGIT Program After Disappointing Lung Cancer Results

6 months ago talkbio0Tagged belrestotug, Clinical Trials, dostarlimab, Drug Development, Galaxies, immuno-oncology, iTeos, Lung-201, Malignant neoplasm of lung, Progression-Free Survival, SmithKline Beecham, TIGIT gene

GSK; iTeos; belrestotug; TIGIT; lung cancer; dostarlimab; clinical trial; drug development; GALAXIES Lung-201; immuno-oncology; progression-free survival

Azafaros Raises €132M in Series B to Fund Phase 3 Trials for Brain-Penetrant Drug

6 months ago talkbio0Tagged Azafaros, Brain-Penetrant Drug, Capital, Clinical Trials, Forbion, Growth, Jeito, Lysosomal Storage Diseases, neuro-metabolic diseases, Neurodegenerative Disorders, nizubaglustat, Phase 3, Series B funding

Azafaros; Series B funding; nizubaglustat; brain-penetrant drug; lysosomal storage disorders; rare neuro-metabolic diseases; phase 3 clinical trials; Jeito Capital; Forbion Growth; neurodegenerative diseases

Fortrea CEO Steps Down Amid Continued Stock Decline Post-Labcorp Spinout

6 months ago talkbio0Tagged CEO, Clinical Trials, CRO, departure - ActRelationshipType, Fortrea, Labcorp, Leadership Change, public company, Stock Decline

Fortrea; Labcorp; CEO departure; stock decline; CRO spinout; leadership change; clinical trials; public company

Where AI Adds Real Value in Clinical Development: 2025 Insights

6 months ago talkbio0Tagged Artificial Intelligence, Clinical Development, Clinical Trials, Data Analysis, Drug Discovery, protocol design, Recruitment, Regulatory Compliance

AI in clinical development; clinical trials; drug discovery; protocol design; patient recruitment; data analysis; regulatory compliance

Accelerating Clinical Trial Excellence: A Seamless IRB & IBC Collaboration

6 months ago talkbio0Tagged Biosafety, Clinical Trials, Collaboration, Efficiency, Ethics Committees, Research, Homo sapiens, IBC, multi-institutional research, regulatory, research, streamlined review

Clinical trials, IRB, IBC, collaboration, streamlined review, multi-institutional research, regulatory efficiency, research acceleration, biosafety, human subject protection

AstraZeneca opens the door to Imfinzi expansion with trial win in high-risk bladder cancer patients

6 months ago talkbio0Tagged Clinical Trials, expansion, high-risk, Imfinzi, Malignant neoplasm of urinary bladder

Imfinzi, Clinical Trials, high-risk, expansion, Malignant neoplasm of urinary bladder

Lilly backs $65M raise for biotech plumbing the ‘dark genome’ with AI

6 months ago talkbio0Tagged Artificial Intelligence, Dark color, Eli, Eli Lilly, Genome, Haya, Long Intergenic Non-Protein Coding RNA, Obesity

Haya, Eli Lilly, Genome, Long Intergenic Non-Protein Coding RNA, Obesity, Aortic Valve Insufficiency, Eli, Dark color

AI Drug Discovery Firm Insitro Lays Off 22% of Workforce Amid Ongoing Biotech Market Turmoil

6 months ago talkbio0Tagged Ambulatory Care Facilities, Artificial Intelligence, Biotech Layoffs, biotechnology layoffs, Drug Discovery, Industry, Insitro, Market, Readiness, restructuring, trends qualifier

Insitro, AI drug discovery, biotechnology layoffs, workforce reduction, tumultuous market, industry restructuring, biotech market trends, clinic readiness, cost-cutting, 2025 biotech layoffs

Marea Therapeutics Reports Positive Phase 2a Results for MAR001 in Lowering Remnant Cholesterol and Triglycerides

6 months ago6 months ago talkbio0Tagged Adverse event, ANGPTL4 gene, Antibodies, Dosage, Embryonic remnant, Hypertriglyceridemia, MAR001, MAR001[1, Phase 2a clinical trial, placebo-adjusted mean reduction, Positive

MAR001, Antibodies, ANGPTL4 gene, Embryonic remnant, Hypertriglyceridemia, Phase 2a clinical trial, Positive, placebo-adjusted mean reduction, Dosage, Adverse event, MAR001[1